Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Liver Failure Clear all
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients

NCT00772148
View directory record Official record
Conditions
Liver Failure
Interventions
LCP -Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tirzepatide in Participants With Impaired Liver Function

NCT03940742
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin

NCT01143246
View directory record Official record
Conditions
Hepatorenal Syndrome
Interventions
Terlipressin, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01860326
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

NCT05260268
View directory record Official record
Conditions
Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
Interventions
TEST Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Suspended No phase listed Observational

Longitudinal Study of Mitochondrial Hepatopathies

NCT01148550
View directory record Official record
Conditions
Acute Liver Failure, Mitochondrial Diseases, End Stage Liver Disease, Respiratory Chain Deficiencies, Mitochondrial, Disorder of Fatty Acid Oxidation
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure

NCT00670124
View directory record Official record
Conditions
Acute Liver Failure, Intracranial Hypertension
Interventions
Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero
Device
Lead sponsor
Rigshospitalet, Denmark
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM

NCT02070315
View directory record Official record
Conditions
Liver Disease, Heart Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 4 Interventional Results available

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

NCT04515797
View directory record Official record
Conditions
Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions
Glecaprevir and Pibrentasvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Improving Communication About Serious Illness

NCT01933789
View directory record Official record
Conditions
Critical Illness, Chronic Disease, Terminal Care, Palliative Care, Communication, Advance Care Planning, Neoplasm Metastasis, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive, Heart Failure, End Stage Liver Disease, Kidney Failure, Chronic
Interventions
Communication Feedback Form for Patients with Serious Illness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Renton, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Correlation Between Release of Cytokines From Liver Graft and Hemodynamic Instability

NCT01120743
View directory record Official record
Conditions
Liver Transplantation
Interventions
Not listed
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional Results available

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

NCT00364689
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib

NCT01387555
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer, HCC
Interventions
JX-594 recombinant vaccina GM-CSF, Best Supportive Care
Biological · Other
Lead sponsor
Jennerex Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
La Jolla, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Withdrawn Phase 3 Interventional

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

NCT02086825
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional

A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions

NCT00144248
View directory record Official record
Conditions
HIV Infections, Hepatic Insufficiency
Interventions
nevirapine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
5
States / cities
Bakersfield, California • San Francisco, California • Albany, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

NCT06619561
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease (cGVHD)
Interventions
Vimseltinib
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
26
States / cities
Duarte, California • Los Angeles, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning

NCT00915681
View directory record Official record
Conditions
Amatoxin Poisoning, Amanita Poisoning, Mushroom Poisoning, Liver Failure
Interventions
Silibinin
Drug
Lead sponsor
Mylan Specialty, LP
Industry
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Somerset, New Jersey • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease

NCT05998330
View directory record Official record
Conditions
Liver Disease Chronic, End Stage Liver DIsease, Cirrhosis, Cirrhosis, Liver, Advanced Cirrhosis
Interventions
LiverPAL
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

NCT01907802
View directory record Official record
Conditions
BRAF Gene Mutation, Hepatic Complication, Renal Failure, Solid Neoplasm
Interventions
Dabrafenib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Not applicable Interventional

Pulmonary Rehabilitation in End-Stage Liver Disease

NCT03266575
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Pulmonary Rehabilitation Exercise, Home Based Exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed No phase listed Observational

Flicker App for Minimal Hepatic Encephalopathy

NCT04415294
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Critical flicker frequency
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Approved For Marketing No phase listed Expanded access

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

NCT01861834
View directory record Official record
Conditions
Cholestasis of Parenteral Nutrition
Interventions
Omegaven 10%
Drug
Lead sponsor
Georgetown University
Other
Eligibility
2 Months to 18 Years
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Jul 21, 2026, 2:19 PM EDT